Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers, aged 18 to 45 years old.~* No active or chronic disease following a detailed medical and surgical history and complete physical examination.~* A BMI between 18 to 30 kg/m2 inclusive.~* Use of a highly effective form of birth control for the duration of the study and until 90 days after the last dose.~Exclusion Criteria:~* Any clinically relevant current or history of conditions or illnesses.~* Clinically significant symptoms of infection within 5 days of the first dosing day or a history of recurrent infections.~* Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse.~* Smokers unable or unwilling to restrict to 5 cigarettes daily during the study and to not smoke during the stay at the clinic.~* Any cardiac abnormalities.~* Blood donation over 450 mL within three months prior to screening.~* Participation in an investigational drug or device study within 3 months prior to dosing.~* Corticosteroid use within 3 months prior to dosing.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part 1: Placebo (PL) (Type: PLACEBO_COMPARATOR): None
- Part 1: Single Ascending Doses (SAD) of RO6836191 (Type: EXPERIMENTAL): None
- Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet (Type: PLACEBO_COMPARATOR): None
- Part 2: PL: NS followed by LS diet (Type: PLACEBO_COMPARATOR): None
- Part 2: RO6836191: LS followed by NS diet (Type: EXPERIMENTAL): None
- Part 2: RO6836191: NS followed by LS diet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).